Carsten Denkert
Impact in
- Cancer Research top 0.02%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.02%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
Papers in
- Cancer Research 211
- Breast Cancer Treatment Studies 136
- Cancer Genomics and Diagnostics 61
- Oncology 235
- Cancer Immunotherapy and Biomarkers 72
- HER2/EGFR in Cancer Research 62
- Cancer Cells and Metastasis 29
- Co-authors
- Jan Budczies (71 shared papers)Manfred Dietel (115 shared papers)Sibylle Loibl (124 shared papers)Wilko Weichert (83 shared papers)Gϋnter von Minckwitz (53 shared papers)Balázs Győrffy (12 shared papers)Silvia Darb‐Esfahani (63 shared papers)Giuseppe Curigliano (8 shared papers)
- Journals
- Annals of Oncology (71 papers)Clinical Cancer Research (26 papers)Journal of Clinical Oncology (19 papers)European Journal of Cancer (18 papers)Breast Cancer Research and Treatment (17 papers)
- Partner nations
- GermanyUnited StatesBelgium
In The Last Decade
Carsten Denkert
538 papers receiving 52.3k citations
Carsten Denkert's Hit Papers
Peers
Comparison fields: 5 of 173
- Cancer Research 16.8k
- Oncology 23.3k
- Immunology 6.3k
- Pulmonary and Respiratory Medicine 6.1k
- Molecular Biology 13.2k
Countries citing papers authored by Carsten Denkert
This map shows the geographic impact of Carsten Denkert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carsten Denkert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carsten Denkert more than expected).
Fields of papers citing papers by Carsten Denkert
This network shows the impact of papers produced by Carsten Denkert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carsten Denkert. The network helps show where Carsten Denkert may publish in the future.
Co-authors
The 25 scholars most cited alongside Carsten Denkert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 556 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 Hit paper breakdown → | 2014 | 2466 |
| 2 | An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients Hit paper breakdown → | 2009 | 2301 |
| 3 | Pembrolizumab for Early Triple-Negative Breast Cancer Hit paper breakdown → | 2020 | 2258 |
| 4 | Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes Hit paper breakdown → | 2012 | 2095 |
| 5 | Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy Hit paper breakdown → | 2017 | 1666 |
| 6 | Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Hit paper breakdown → | 2009 | 1470 |
| 7 | Breast cancer Hit paper breakdown → | 2021 | 1218 |
| 8 | Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial Hit paper breakdown → | 2014 | 1066 |
| 9 | Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization Hit paper breakdown → | 2012 | 1047 |
| 10 | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 Hit paper breakdown → | 2017 | 915 |
| 11 | Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers Hit paper breakdown → | 2014 | 868 |
| 12 | Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial Hit paper breakdown → | 2014 | 799 |
| 13 | Clinical relevance of host immunity in breast cancer: from TILs to the clinic Hit paper breakdown → | 2015 | 721 |
| 14 | Molecular alterations in triple-negative breast cancer—the road to new treatment strategies Hit paper breakdown → | 2016 | 703 |
| 15 | Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers Hit paper breakdown → | 2019 | 651 |
| 16 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors Hit paper breakdown → | 2017 | 629 |
| 17 | A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study Hit paper breakdown → | 2019 | 562 |
| 18 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research Hit paper breakdown → | 2017 | 553 |
| 19 | Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2023 | 521 |
| 20 | Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 Hit paper breakdown → | 2019 | 519 |
About Carsten Denkert
Carsten Denkert is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Reproductive Medicine and Molecular Biology, having authored 556 papers that have together received 53.2k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (136 papers), Cancer Immunotherapy and Biomarkers (72 papers), HER2/EGFR in Cancer Research (62 papers), Cancer Genomics and Diagnostics (61 papers), Advanced Breast Cancer Therapies (35 papers), Ovarian cancer diagnosis and treatment (32 papers), Immunotherapy and Immune Responses (30 papers) and Cancer Cells and Metastasis (29 papers). The work is most often cited by research in Cancer Research (16.8k citations), Oncology (23.3k citations), Immunology (6.3k citations), Pulmonary and Respiratory Medicine (6.1k citations) and Molecular Biology (13.2k citations). Carsten Denkert has collaborated with scholars based in Germany, United States and Belgium. Frequent co-authors include Jan Budczies, Manfred Dietel, Sibylle Loibl, Wilko Weichert, Gϋnter von Minckwitz, Balázs Győrffy, Silvia Darb‐Esfahani, Giuseppe Curigliano, Aurelia Noske and András Lánczky. Their work appears in journals such as Annals of Oncology, Clinical Cancer Research, Journal of Clinical Oncology, European Journal of Cancer and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.